Pitchaiah Mandava1, Santosh B Murthy2, Neel Shah2, Yves Samson2, Marek Kimmel2, Thomas A Kent2. 1. From the Michael E. DeBakey VA Medical Center Stroke Program (P.M., N.S.) and Analytical Software and Engineering Research Laboratory, Department of Neurology (P.M., N.S., T.A.K.), Baylor College of Medicine, Houston, TX; Department of Neurology (S.B.M.) and Clinical and Translational Neuroscience Unit (S.B.M.), Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY; APHP (Y.S.), Urgences Cerebro-Vasculaire, Pitié-Salpêtrière, and UPMC Paris Sorbonne Universités (Y.S.), Paris, France; Departments of Statistics and Bioengineering (M.K.) and Chemistry (T.A.K.), Rice University, Houston; Institute of Biosciences and Technology (IBT) (T.A.K.), Texas A&M Health Science Center-Houston Campus; and Department of Neurology (T.A.K.), Houston Methodist Hospital and Research Institute, TX. pmandava@bcm.edu. 2. From the Michael E. DeBakey VA Medical Center Stroke Program (P.M., N.S.) and Analytical Software and Engineering Research Laboratory, Department of Neurology (P.M., N.S., T.A.K.), Baylor College of Medicine, Houston, TX; Department of Neurology (S.B.M.) and Clinical and Translational Neuroscience Unit (S.B.M.), Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY; APHP (Y.S.), Urgences Cerebro-Vasculaire, Pitié-Salpêtrière, and UPMC Paris Sorbonne Universités (Y.S.), Paris, France; Departments of Statistics and Bioengineering (M.K.) and Chemistry (T.A.K.), Rice University, Houston; Institute of Biosciences and Technology (IBT) (T.A.K.), Texas A&M Health Science Center-Houston Campus; and Department of Neurology (T.A.K.), Houston Methodist Hospital and Research Institute, TX.
Abstract
OBJECTIVE: To develop models of outcome for intracerebral hemorrhage (ICH) to identify promising and futile interventions based on their early phase results without need for correction for baseline imbalances. METHODS: We developed a pooled outcome model from the control arms of randomized control trials and tested different interventions against the model at comparable baseline conditions. Eligible clinical trials and large case series were identified from multiple library databases. Models based on baseline factors reported in the control arms were tested for the ability to predict functional outcome (modified Rankin Scale score) and mortality. Interventions were grouped into blood pressure control, fibrinolytic-assisted hematoma evacuation, hemostatic medications, and neuroprotective agents. Statistical intervals around the model were generated at the p = 0.1 level to screen how each trial's outcome compared to expected outcome. RESULTS: Fourteen control arms with 3,386 patients were used to develop 7 alternate models for functional outcome. The model incorporating baseline NIH Stroke Scale, age, and hematoma volume yielded the best fit (adjusted R 2 = 0.89). All early phase treatments that eventually resulted in negative late phase trials were identified as negative by this method. Early phase fibrinolytic-assisted hematoma evacuation studies showed the most promise trending toward improved functional outcome with no suggestion of an increase in mortality, supporting its further study. CONCLUSIONS: We successfully developed an outcome model for ICH that identified interventions destined to be negative while identifying a promising one. Such an approach may assist in prioritizing resources prior to multicenter trial.
OBJECTIVE: To develop models of outcome for intracerebral hemorrhage (ICH) to identify promising and futile interventions based on their early phase results without need for correction for baseline imbalances. METHODS: We developed a pooled outcome model from the control arms of randomized control trials and tested different interventions against the model at comparable baseline conditions. Eligible clinical trials and large case series were identified from multiple library databases. Models based on baseline factors reported in the control arms were tested for the ability to predict functional outcome (modified Rankin Scale score) and mortality. Interventions were grouped into blood pressure control, fibrinolytic-assisted hematoma evacuation, hemostatic medications, and neuroprotective agents. Statistical intervals around the model were generated at the p = 0.1 level to screen how each trial's outcome compared to expected outcome. RESULTS: Fourteen control arms with 3,386 patients were used to develop 7 alternate models for functional outcome. The model incorporating baseline NIH Stroke Scale, age, and hematoma volume yielded the best fit (adjusted R 2 = 0.89). All early phase treatments that eventually resulted in negative late phase trials were identified as negative by this method. Early phase fibrinolytic-assisted hematoma evacuation studies showed the most promise trending toward improved functional outcome with no suggestion of an increase in mortality, supporting its further study. CONCLUSIONS: We successfully developed an outcome model for ICH that identified interventions destined to be negative while identifying a promising one. Such an approach may assist in prioritizing resources prior to multicenter trial.
Authors: Andrea Morotti; H Bart Brouwers; Javier M Romero; Michael J Jessel; Anastasia Vashkevich; Kristin Schwab; Mohammad Rauf Afzal; Christy Cassarly; Steven M Greenberg; Renee Hebert Martin; Adnan I Qureshi; Jonathan Rosand; Joshua N Goldstein Journal: JAMA Neurol Date: 2017-08-01 Impact factor: 18.302
Authors: M Zuccarello; T Brott; L Derex; R Kothari; L Sauerbeck; J Tew; H Van Loveren; H S Yeh; T Tomsick; A Pancioli; J Khoury; J Broderick Journal: Stroke Date: 1999-09 Impact factor: 7.914
Authors: Timothy C Morgan; Jesse Dawson; Danielle Spengler; Kennedy R Lees; Chanel Aldrich; Nishant K Mishra; Karen Lane; Terence J Quinn; Marie Diener-West; Christopher J Weir; Peter Higgins; Mark Rafferty; Katie Kinsley; Wendy Ziai; Issam Awad; Matthew R Walters; Daniel Hanley Journal: Stroke Date: 2013-01-31 Impact factor: 7.914
Authors: Barbara A Gregson; Joseph P Broderick; Ludwig M Auer; Hunt Batjer; Xian-Cheng Chen; Seppo Juvela; Lewis B Morgenstern; George C Pantazis; Onno P M Teernstra; Wen-Zhi Wang; Mario Zuccarello; A David Mendelow Journal: Stroke Date: 2012-04-17 Impact factor: 7.914
Authors: M Irem Baharoglu; Charlotte Cordonnier; Rustam Al-Shahi Salman; Koen de Gans; Maria M Koopman; Anneke Brand; Charles B Majoie; Ludo F Beenen; Henk A Marquering; Marinus Vermeulen; Paul J Nederkoorn; Rob J de Haan; Yvo B Roos Journal: Lancet Date: 2016-05-10 Impact factor: 79.321
Authors: A David Mendelow; Barbara A Gregson; Elise N Rowan; Gordon D Murray; Anil Gholkar; Patrick M Mitchell Journal: Lancet Date: 2013-05-29 Impact factor: 79.321
Authors: David Haupenthal; Joji B Kuramatsu; Bastian Volbers; Jochen A Sembill; Anne Mrochen; Stefanie Balk; Philip Hoelter; Hannes Lücking; Tobias Engelhorn; Arnd Dörfler; Stefan Schwab; Hagen B Huttner; Maximilian I Sprügel Journal: JAMA Netw Open Date: 2021-07-01